Kairos Pharma, Ltd. (KAPA)
:KAPA
Total Valuation
Kairos Pharma, Ltd. has a market cap or net worth of $12.46M. The enterprise value is $7.97M.
Market Cap$12.46M
Enterprise Value$7.97M
Share Statistics
Kairos Pharma, Ltd. has 21,411,198 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,411,198
Owned by Insiders36.51%
Owned by Institutions0.21%
Financial Efficiency
Kairos Pharma, Ltd.’s return on equity (ROE) is -0.86 and return on invested capital (ROIC) is -87.87%.
Return on Equity (ROE)-0.86
Return on Assets (ROA)-0.83
Return on Invested Capital (ROIC)-87.87%
Return on Capital Employed (ROCE)-0.88
Revenue Per Employee0.00
Profits Per Employee-5.45M
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kairos Pharma, Ltd. is ―. Kairos Pharma, Ltd.’s PEG ratio is -0.08.
PE Ratio―
PS Ratio0.00
PB Ratio2.06
Price to Fair Value2.06
Price to FCF-3.80
Price to Operating Cash Flow-3.18
PEG Ratio-0.08
Income Statement
In the last 12 months, Kairos Pharma, Ltd. had revenue of 0.00 and earned -5.45M in profits. Earnings per share was -0.30.
Revenue0.00
Gross Profit0.00
Operating Income-5.57M
Pretax Income-5.45M
Net Income-5.45M
EBITDA-5.29M
Earnings Per Share (EPS)-0.30
Cash Flow
In the last 12 months, operating cash flow was -3.44M and capital expenditures 0.00, giving a free cash flow of -3.44M billion.
Operating Cash Flow-3.44M
Free Cash Flow-3.44M
Free Cash Flow per Share-0.16
Dividends & Yields
Kairos Pharma, Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.96
52-Week Price Change-41.31%
50-Day Moving Average0.61
200-Day Moving Average0.90
Relative Strength Index (RSI)45.52
Average Volume (3m)1.08M
Important Dates
Kairos Pharma, Ltd. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Kairos Pharma, Ltd. as a current ratio of 27.07, with Debt / Equity ratio of 0.00%
Current Ratio27.07
Quick Ratio27.07
Debt to Market Cap0.00
Net Debt to EBITDA0.85
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Kairos Pharma, Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kairos Pharma, Ltd. EV to EBITDA ratio is -1.63, with an EV/FCF ratio of -2.50.
EV to Sales0.00
EV to EBITDA-1.63
EV to Free Cash Flow-2.50
EV to Operating Cash Flow-2.50
Balance Sheet
Kairos Pharma, Ltd. has $4.49M in cash and marketable securities with $0.00 in debt, giving a net cash position of $4.49M billion.
Cash & Marketable Securities$4.49M
Total Debt$0.00
Net Cash$4.49M
Net Cash Per Share$0.21
Tangible Book Value Per Share$0.34
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kairos Pharma, Ltd. is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside1279.31% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―